Table 2 Tumour immune microenvironment according to the clinical setting

From: Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours

Variables

TKI-naive group (n = 20), median (IQR 25%–75%)

IM-PD group (n = 30), median (IQR 25%–75%)

IM-PD/SU-treated group (n = 31), median (IQR 25%–75%)

P value

CD3+ T cell

112.1 (30.5–575.5)

63.5 (14.1–342.3)

393.0 (88.9–690.0)

0.19

CD8+ CD3+ T cell

4.9 (1.0–46.1)

4.9 (0.6–26.8)

27.1 (8.0–65.7)

0.16

FoxP3+ CD3+ cell

3.9 (0.1–24.1)

3.6 (0.6–8.2)

28.0 (6.0–71.1)

0.05

CD68+ CD204+ cell

9.1 (0.3–47.3)

7.2 (1.8–27.7)

23.2 (6.8–128.3)

0.001

CD68+ CD204- cell

6.3 (2.6–34.1)

8.5 (4.4–18.8)

15.0 (5.9–56.4)

0.32

PD-1+ CD3+ T cell

1.8 (0.3–16.2)

0.6 (0.0–6.4)

10.4 (3.7–52.2)

0.02

PD-L1+ CD3+ T cell

0 (0.0–1.4)

0.0 (0.0–0.1)

0.9 (0.0–49.3)

0.02

Ki-67+ CD3+ T cell

0.3 (0.0–2.3)

0.3 (0.1–1.8)

7.2 (0.6–17.0)

0.02

Ki-67+ CD8+ T cell

0.1 (0.0–1.1)

0.5 (0.0–5.2)

5.8 (0.9–20.1)

0.16

TIM-3+ CD3+ T cell

0.0 (0.0–1.5)

0.0 (0.0–0.4)

1.2 (0–6.2)

0.008

LAG-3+ CD3+ T cell

0.1 (0.0–1.1)

0.1 (0.0–0.7)

0.9 (0.3–6.2)

0.09

PD-L1+ DOG-1+ tumour cell

0.0 (0.0–7.6)

2.0 (0.6–15.5)

6.9 (0.3–551.7)

0.07

Ki-67+ DOG-1+ tumour cell

9.1 (0.2–47.3)

104.6 (14.0–207.2)

203.6 (44.9–342.0)

0.02

  1. Values are expressed as number of cells per mm2
  2. TKI tyrosine kinase inhibitor, IM-PD imatinib-progressed and no exposure to sunitinib or regorafenib, IM-PD/SU-treated imatinib-progressed and sunitinib and/or regorafenib-treated
  3. Bold values indicate statistical significance p < 0.05
Back to article page